Comparison of Different Systemic Therapeutic Regimes in Resectable Soft-Tissue Sarcoma-Results of a Network Meta-Analysis.

Jan HaussmannChristiane MatuschekEdwin Boelke Bálint Tamaskovics Stefanie CorradiniRüdiger WessalowskiKitti MaasLivia SchmidtKlaus OrthMatthias PeiperVerena KeitelTorsten FeldtBjörn-Erik Ole JensenTom LueddeJohannes FischerWolfram Trudo KnoefelHany AshmawyAlessia PedotoaKai KammersWilfried Budach

Published in: Cancers (2021)

Standardized chemotherapy in high-risk soft-tissue sarcoma appears to be of added value irrespective of timing. The benefit of adjuvant chemotherapy seems to be restricted to male patients. The addition of regional hyperthermia to neodjuvant chemotherapy achieved the best effect sizes and might warrant further investigation.

Keyphrases

locally advanced
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
patient reported outcomes
radiation therapy